Updated Survival Outcomes From PACIFIC Trial of Immunotherapy for Stage III Lung Cancer
Posted: Friday, July 16, 2021
A primary analysis of durvalumab under the ‘PACIFIC regimen’ showed improved survival outcomes in patients with unresectable stage III non–small cell lung cancer (NSCLC) given the monoclonal antibody durvalumab after chemoradiotherapy. Now, recent 5-year data from the phase III PACIFIC trial continue to show sustained overall survival, with almost a third of patients on the treatment regimen alive and free of disease progression. David R. Spigel, MD, of the Sarah Cannon Research Institute, Nashville, and colleagues presented their survival update during the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting (Abstract 8511).
“An estimated 42.9% of patients randomized to durvalumab remain alive at 5 years,” reported the study investigators.
Patients with a WHO performance status score of 0 or 1 and any tumor PD-L1 status whose disease did not progress after two or more overlapping cycles of concurrent chemoradiation therapy were included in the analysis. About 709 patients were randomly assigned 1 to 42 days following concurrent chemoradiation therapy 12 months of 10 mg/kg of intravenous durvalumab every 2 weeks or a placebo.
As of January 11, 2021, the median follow-up duration of 34.2 months (range = 0.2–74.7 months), the updated overall survival (median 47.5 vs. 29.1 months) and progression-free survival (median 16.9 vs. 5.6 months) were consistent with primary analyses results. The 60-month overall survival rates were 42.9% in patients given durvalumab than 33.4% in patients given a placebo. The 60-month progression-free survival rates were 33.1% and 19%, respectively.
Disclosure: For full disclosures of the study authors, visit coi.asco.org.